Clinical Trial

A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS

Study acronym: EPO-PRETAR
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is an open-label, randomized, multicenter, phase III study Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks: * Either at diagnosis Or * at the Hb threshold chosen for RBC transfusions (must be \< 9g/dl)
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2017-07-18; most recent amendment 2025-03-06.
Status change: Recruiting → Active, Not Recruiting 2025-03-06
Status change: Not Yet Recruiting → Recruiting 2018-02-01
Trial Details
NCT Number NCT03223961
Lead Sponsor Groupe Francophone des Myelodysplasies
Conditions Myelodysplastic Syndromes
Enrollment 124 participants
Start Date 2018-03-26
Primary Completion 2023-09-21 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-11